Conference Coverage

Prolia tops risedronate at 2 years in steroid-induced osteoporosis

Publish date: July 10, 2018

 

REPORTING FROM THE EULAR 2018 CONGRESS

SOURCE: Saag KG et al. Ann Rheum Dis. 2018;77(Suppl 2):218. Abstract OP0345.

Pages

Recommended Reading

PBC linked to low BMD, increased risk of osteoporosis
MDedge Rheumatology
VIDEO: Dr. Andrew Kaunitz’s top lessons from NAMS 2017
MDedge Rheumatology
Use of opioids, SSRIs linked to increased fracture risk in RA
MDedge Rheumatology
European Commission expands denosumab indication
MDedge Rheumatology
Spine fracture risk may be increased in IBD patients
MDedge Rheumatology
VIDEO: BMI helps predict bone fragility in obese patients
MDedge Rheumatology
FDA approves Prolia for glucocorticoid-induced osteoporosis
MDedge Rheumatology
EULAR scientific program highlights spectrum of translational research
MDedge Rheumatology
What underlies post–bariatric surgery bone fragility?
MDedge Rheumatology
Bisphosphonate ‘holidays’ exceeding 2 years linked to increased fractures
MDedge Rheumatology